

1 *Supplementary Table 1: Characterization of primary AML samples: All*  
2 *samples were collected and frozen as viable cells prior to study. Morphologic*  
3 *assignment of phenotype used either French American British or World*  
4 *Health Organization nomenclature at discretion of hematopathologist. NA –*  
5 *not available. PB-MNC – peripheral blood mononuclear cell fractions; such*  
6 *samples were used only if >70% blasts. \*Patient demonstrated both Flt3 ITD*  
7 *and D8365 mutations. #AML arising after prior diagnosis of MDS.*  
8